Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2018 1
2021 2
2022 2
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Results by year

Filters applied: . Clear all
Page 1
Outcomes following posttransplant virus-specific T-cell therapy in patients with sickle cell disease.
Kinoshita H, Mandava M, Jensen-Wachspress M, Lang H, Joy E, Tanna J, McCann CD, O'Brien S, Burnett S, Shibli A, Hoq F, Bhatia M, Hanley PJ, Dávila Saldaña B, Mahadeo KM, Bollard CM, Keller MD, Abraham A. Kinoshita H, et al. Blood Adv. 2023 May 23;7(10):2105-2116. doi: 10.1182/bloodadvances.2022008219. Blood Adv. 2023. PMID: 36516084 Free PMC article.
Robust Antibody and T Cell Responses to SARS-CoV-2 in Patients with Antibody Deficiency.
Kinoshita H, Durkee-Shock J, Jensen-Wachspress M, Kankate VV, Lang H, Lazarski CA, Keswani A, Webber KC, Montgomery-Recht K, Walkiewicz M, Notarangelo LD, Burbelo PD, Fuss I, Cohen JI, Bollard CM, Keller MD. Kinoshita H, et al. J Clin Immunol. 2021 Aug;41(6):1146-1153. doi: 10.1007/s10875-021-01046-y. Epub 2021 May 13. J Clin Immunol. 2021. PMID: 33983545 Free PMC article.
Outcome of donor-derived TAA-T cell therapy in patients with high-risk or relapsed acute leukemia post allogeneic BMT.
Kinoshita H, Cooke KR, Grant M, Stanojevic M, Cruz CR, Keller M, Fortiz MF, Hoq F, Lang H, Barrett AJ, Liang H, Tanna J, Zhang N, Shibli A, Datar A, Fulton K, Kukadiya D, Zhang A, Williams KM, Dave H, Dome JS, Jacobsohn D, Hanley PJ, Jones RJ, Bollard CM. Kinoshita H, et al. Blood Adv. 2022 Apr 26;6(8):2520-2534. doi: 10.1182/bloodadvances.2021006831. Blood Adv. 2022. PMID: 35244681 Free PMC article. Clinical Trial.
SARS-CoV-2-Specific T Cell Responses Are Stronger in Children With Multisystem Inflammatory Syndrome Compared to Children With Uncomplicated SARS-CoV-2 Infection.
Conway SR, Lazarski CA, Field NE, Jensen-Wachspress M, Lang H, Kankate V, Durkee-Shock J, Kinoshita H, Suslovic W, Webber K, Smith K, Cohen JI, Burbelo PD, Zhang A, Teach SJ, Ibeh T, Delaney M, DeBiasi RL, Keller MD, Bollard CM. Conway SR, et al. Among authors: kinoshita h. Front Immunol. 2022 Jan 18;12:793197. doi: 10.3389/fimmu.2021.793197. eCollection 2021. Front Immunol. 2022. PMID: 35116027 Free PMC article.
Durable immunity to EBV after rituximab and third-party LMP-specific T cells: a Children's Oncology Group study.
Wistinghausen B, Toner K, Barkauskas DA, Jerkins LP, Kinoshita H, Chansky P, Pezzella G, Saguilig L, Hayashi RJ, Abhyankar H, Scull B, Karri V, Tanna J, Hanley P, Hermiston ML, Allen CE, Bollard CM. Wistinghausen B, et al. Among authors: kinoshita h. Blood Adv. 2024 Mar 12;8(5):1116-1127. doi: 10.1182/bloodadvances.2023010832. Blood Adv. 2024. PMID: 38163318 Free PMC article.